Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 14, 2025

Galapagos Announces Oral Presentations at EHA and ICML 2025 Featuring Promising New Data from ATALANTA-1 study of Investigational CAR-T Candidate GLPG5101
Mechelen, Belgium; May 14, 2025, 22:01 CET; Galapagos NV (Euronext …

Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
MZE829 Phase 2 HORIZON Trial Enrolling Patients with APOL1 Kidney Disease; Initial Data Expected in Q1 2026 MZE782 Phase 1 Healthy Volunteer Trial Ongoing; Initial Data Expected in Q3 2025 Strong Balance Sheet with $294.4 Million in Cash and Cash …

Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for …

Bionano Reports First Quarter 2025 Results and Highlights Recent Business Progress
SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represents the first full quarter of execution after shifting strategy …

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results
On track to report topline results from Phase 2 BESTOW trial in kidney transplantation in fourth quarter of 2025 Tegoprubart used as a key component of immunosuppression regimen in its second transplant of a genetically modified pig kidney into a human …

Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 …

Monogram Technologies Reports First Quarter 2025 Financial Results
Receives FDA Clearance for the mBôs™ TKA System Groundbreaking Trial Set to Deliver one of the World’s First Autonomous Saw-Based Robotic TKA Surgeries on Live Patients Management to Host Business Update Conference Call Today at 4:30 p.m. Eastern Time …

MDxHealth Reports Q1-2025 Results
Year-over-year Q1 revenues increase by 22% to $24.3 million 71% year-over-year improvement in adjusted EBITDA in first quarter Conference call with Q…

Serina Therapeutics Makes Grants to New Employees Under Inducement Plan
HUNTSVILLE, AL, May 14, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ …

US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030
Delhi, May 14, 2025 (GLOBE NEWSWIRE) -- US Orphan Designated Drugs Market Opportunity, Drugs Sales, Price, Dosage and Clinical Trials Insight 2030 Report Offering and Highlights: US Orphan Designated Drugs Market Opportunity: > US$ 190 Billion By 2030 …

Aptose Selected for Prestigious Oral Presentation of Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress
Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML Oral presentation at EHA will include updated data at the 40 mg and 80 mg dose levels and longer duration SAN DIEGO and …

Sevaro Launches Nationwide Stroke Awareness Campaign With Racecars, Storybooks, and Student Heroes
CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- A stroke happens every 40 seconds in the U.S.—and every minute without treatment can cost a person 1.9 million brain cells. This May, during Stroke Awareness Month Sevaro Health is shifting the narrative— …

The Best Steroids for Cutting, Muscle Growth & Strength for Weight Training - Top Legal Steroid Stacks for Bulking, Fat Loss, Getting Shredded & Ripped - CrazyBulk
New York City, NY, May 14, 2025 (GLOBE NEWSWIRE) -- For serious bodybuilders and weightlifters, achieving fast muscle growth and that shredded look takes more than just hard work in the gym. The right steroid stack will push past limits, pack on lean …

REPEAT/Media Advisory/OHC - Day of Action at Ontario Legislature to Stop Hospital Closures
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- On Wednesday May 14, people from across Ontario will be heading into the Ontario Legislature for a “Day of Action” to ask the Ford government to stop closing their local hospitals and to provide the resources …

Angelini Ventures Invests into $39 Million Series A Extension Round for Therini Bio, a Clinical Stage Company Developing Fibrin-targeting Immunotherapies for Neurodegenerative Diseases
Angelini Ventures joins top-tier investor syndicate Investment will fund Phase 1b studies evaluating Therini Bio’s lead candidate, THN391, for the treatment of Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME), as well as support development of a …

“Say the ‘S’ word:” Physician-Patient Alliance for Health & Safety Launches CME Sepsis Courses
Chicago, IL, May 14, 2025 (GLOBE NEWSWIRE) -- “Say the ‘S’ word:” Physician-Patient Alliance for Health …

Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress
– Ziftomenib combined with 7+3 in 1L NPM1-m or KMT2A-r AML patients selected for oral presentation on Thursday, June 12th – – Updated dataset to be presented in oral presentation at EHA2025 Congress – SAN DIEGO and TOKYO, May 14, 2025 (GLOBE NEWSWIRE) -- …

Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
- Angelini Ventures and Apollo Health Ventures join existing top-tier investor syndicate - Follows original $36M Series A raise and brings Series A total to $75M - Proceeds are being used to fund Phase 1b Alzheimer’s and DME studies, and bispecific …

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter …

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma
SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that …